• manuel.scimeca@unicamillus.org

Manuel Scimeca

Medical Oncology - Med/06
Fundamentals of Histopathology/Pathological Anatomy - Med/08


Biologist – Bachelor degree in “Cellular and molecular Biology” (2008);  Master degree in “Medical Biotechnology” (2011), PhD in “Medical Biotechnology and Translational Medicine” (2015).
Professor at University of Rome “Tor Vergata, “San Raffaele” University and ”Saint Camillus International University of Health and Medical Sciences”.
Coordinator of Anatomic Pathology laboratory, (University of Rome “Tor Vergata”) and Histology laboratory research (OrchideaLab).
Post-Doc position at University of Rome “Tor Vergata” for the project “Management of oncological patients”.
Participant in the European group of breast pathology studies.
Member of the “Società Italiana di Anatomia Patologica” (SIAPEC).
He has currently employs all basic and advanced techniques of the histological area such as optical and electron microscopy, immunohistochemistry, in situ hybridization, design and construction of Tissue Micro arrays (TMA), laser microdissection and capture.
Co-Founder of:
– “TMALab S.r.l.” Spin-Off at University of Rome Tor Vergata, Rome, Italy.
– “OrchidealLab S.r.l.”.
Author of more of sixty scientific papers published in international Journals and 1 chapter in book.
In addition, he has held over 30 invited lectures in national and international congresses and/or institutes focused on the histopathological studies of the main human cancers and on bone metabolism.
Patents: Brev/gc [A18256-00], Pentraxin 3 (PTX3) protein for the treatment and in vitro diagnosis of osteoporosis.
13/04/2016 Prize Gisoos _Thesis Project”Il Bio-accumulo di Metalli Pesanti nella patogenesi dell’Osteoporosi”.
16/12/2016 Ortomed Congress 2016, Firenze – Prize “Best Scientific Contribution” for the poster “PTX3: un nuovo mediatore del metabolism osseo e del differenziamento osteoblastico”.
14/12/2017 Ortomed Congress 2017, Firenze – Prize “Best Scientific Contribution” for the Oral Presentation “Profilo cellulare e molecolare della sarcopenia nei pazienti osteoporotici e osteoartrosici”.